Divergences between ACOG and international guidelines suggest opportunities to strengthen U.S. HDP prevention and management, including incorporating Black race and low income as independent aspirin prophylaxis risk criteria.
Abstract
Background
Women in the United States (U.S.) experience higher maternal morbidity and mortality than other high-income countries, with hypertensive disorders of pregnancy (HDP) among the most common, preventable contributors. Despite evidence supporting pharmacologic intervention, American College of Obstetricians and Gynecologists (ACOG) guidelines prioritize surveillance over active HDP management. This study compared ACOG guidance for HDP prevention, diagnosis, management, and postpartum follow-up with recommendations from six high-income countries.
Methods
Document analysis compared national HDP guidelines from Australia and New Zealand, Canada, Japan, Trinidad and Tobago, and the United Kingdom with ACOG guidance, systematically coded across five domains: (1) first-trimester risk assessment, (2) preeclampsia prevention, (3) antihypertensive medication initiation thresholds, (4) postpartum monitoring, and (5) patient education.
Results
Divergences exist between ACOG and international guidelines across all domains. Most notably, ACOG recommends initiating antihypertensive medication at ≥ 160/110 mmHg for gestational hypertension, while international guidelines recommend initiation at ≥ 140/90 mmHg with specified targets. International guidelines also recommend calcium supplementation for low dietary intake, structured postpartum monitoring beyond 8 weeks, home-based monitoring, mental health screening, and education on long-term cardiovascular risk, elements underspecified in ACOG guidance. ACOG incorporates Black race and low income as independent aspirin prophylaxis risk criteria, though using race as a proxy for racism raises equity questions. No reviewed guideline explicitly defines midwifery roles in HDP management.
Discussion
Substantial divergences between ACOG and international guidelines suggest opportunities to strengthen U.S. HDP prevention and management. Recent trial evidence and persistent, inequitable maternal mortality support moving beyond voluntary recommendations toward accountability mechanisms driving consistent, evidence-based care.
A scoping review protocol is outlined, using the JBI methodology, to map and synthesize existing evidence on the barriers and facilitators that influence the health-seeking behaviours of pregnant women with HDP in LMICs.
Hypertensive disorders of pregnancy (HDP) including chronic hypertension, gestational hypertension preeclampsia and eclampsia are a leading cause of maternal and perinatal mortality in Nigeria and globally and increase the risk for future cardiovascular disease among women of reproductive age (WRA). The quality improve...
U. Okoli, Sylverius Obafemi, C. Okpe et al.· PLoS ONE· 0 citations
BACKGROUND
Hypertensive disorders of pregnancy (HDP) affect 8-10% of pregnancies. They are an important cause of maternal morbidity, with crucial implications for long-term cardiovascular health. Whilst antenatal blood pressure (BP) management is well described and evidence-based, postnatal treatment thresholds are hig...
Chloé Moran, Kimberly Lim Xinyi, Natalie Barry et al.· Pregnancy Hypertension· 0 citations
A standardized multicenter pilot is proposed comprising documented risk communication and a named receiving provider before discharge; blood-pressure evaluation within 72 hours for women with severe hypertension and no later than 7–10 days for other women with hypertensive disorders; structured assessment at 6–12 weeks...
N. H. Tran, Kanchana Piboon· International Journal of Wom...· 0 citations
Hypertensive disorders of pregnancy (HDP) affect approximately 1 in 7 pregnancies in the United States and are increasingly recognized as early and independent markers of lifetime cardiovascular disease. This review provides an update of the evidence for classification, pathophysiology, and management of HDP with an em...
Jessica Gottula, Tiffany Corlin, M. Burn et al.· Current Cardiovascular Risk...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.